Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Date:8/22/2007

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company'
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the following equities: ... ABT ), Hologic Inc. (NASDAQ: HOLX ... PLC (NYSE: COV). Free research on these five companies can ... markets on Thursday, October 30, 2014, ended on a positive ... up 1.30% and the NASDAQ Composite closed at 4,566.14, up ...
(Date:10/31/2014)...  Zebra Imaging, Inc., the world,s foremost provider ... strategic partnership with the Zygote Media Group Inc., ... biomedical models for animation and visual effects, to ... maintains the world,s most comprehensive library of accurate ... development of high-end solid 3D anatomy models for ...
(Date:10/31/2014)... , Oct. 31, 2014  Australian biopharmaceutical company Specialised ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will ... patients with metastatic pancreatic cancer from 1 November. ... cancer is the 5 th most common cause ... all cancer deaths, with the lowest 5-year survival of ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8
... The delay in round two of Medicare,s controversial "competitive" ... that program,s severe design flaws. Opposition to the program ... among members of Congress where one fifth of the ... of the program. "The federal government,s ...
... Care Breast Center at the Helen F. Graham Cancer ... breast Magnetic Resonance Imaging (MRI) by the American College of ... The Christiana Care Breast Center is the only ... the breast offers valuable information about many breast conditions that ...
Cached Medicine Technology:Delay of Medicare Bidding Program for Home Medical Equipment Underscores Severe Problems with Program; Support Surges for Bipartisan Bill to Repeal the Bid Program 2Delay of Medicare Bidding Program for Home Medical Equipment Underscores Severe Problems with Program; Support Surges for Bipartisan Bill to Repeal the Bid Program 3
(Date:10/31/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... the U.S. indoor air quality (IAQ) market is expected to ... growth rate (CAGR) of 7% over the next five years. ... CAGR of 7.4%. , Since 2012, continuing media attention ... of infectious diseases such as bird flu and the increase ...
(Date:10/31/2014)... Boca Raton, FL (PRWEB) October 31, 2014 ... wellness company founded on the highest principles of patient ... Lifescript , a leading health and wellness website, to ... those living with diabetes. , The Diabetes Health ... tips and recipes for those living with diabetes. Content ...
(Date:10/31/2014)... News) -- Carving pumpkins and trick-or-treating may seem like ... emergency rooms in the United States every year, experts ... fifth highest number of ER visits involving children aged ... the National Electronic Injury Surveillance System. Nearly ... the American Academy of Orthopaedic Surgeons and the Pediatric ...
(Date:10/31/2014)... to generic hormone therapy medicines improves the chances that ... a new study found. "We know that hormone ... reduce recurrence by up to 50 percent," study leader ... Columbia University Medical Center in New York City, said ... by our group and others has shown that a ...
(Date:10/31/2014)... News) -- There are clear differences in the brains ... of healthy people, new research indicates. Scientists ... could help doctors diagnose this baffling condition and shed ... syndrome are often misdiagnosed or labeled as hypochondriacs. ... "we found that [chronic fatigue syndrome] patients, brains diverge ...
Breaking Medicine News(10 mins):Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:Halloween at the ER Is No Treat 2Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3
... service was added to lunchroom, study found , FRIDAY, Dec. ... the school lunch room helps elementary school students eat significantly ... of California, Los Angeles, study included 337 children in grades ... were interviewed before and after their schools started offering a ...
... focus On Software & Software Services Yields Two ... Genstar Capital, LLC, a middle,market private equity firm ... sciences, healthcare services, industrial technology, software and,software services, ... a,Managing Director., "We have been extremely pleased ...
... than 250,000 in U.S., CHICAGO, Dec. 21 ... What:, On Wednesday, December 26, CBS at ... Gala in which Leon Fleisher, award winning pianist,and conductor, ... the most,gifted pianists of his generation, Fleisher,s career was ...
... two conditions are sometimes closely linked, research suggests , FRIDAY, ... the lives of people with diabetes, concludes a University of ... the journal Diabetes Care . , It found that ... depression reduced the risk of death over five years by ...
... England, Dec. 21 ,Reckitt Benckiser Group plc (RB.L) ... offer (the "Offer") for all of the,outstanding shares ... ),("Adams")., As announced on December 10, 2007, ... which it will offer Adams stockholders US$60.00,in cash ...
... INC.,(Nasdaq: RESP ) today announced it has entered ... Electronics (AEX: PHI, NYSE: PHG),(Philips) will commence a tender ... for USD 66.00 in cash per share, or a ... price represents a,premium of approximately 31% over Respironics, average ...
Cached Medicine News:Health News:School Salad Bar Boosts Kids' Fruit, Veggie Intake 2Health News:Genstar Capital Appoints Mark Hanson to Managing Director 2Health News:Expert on Neurological Disease Available for Comment as Recovered Patient, Leon Fleischer, Receives Kennedy Center Award 2Health News:Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics 2Health News:Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics 3Health News:Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5
... System aids in the rapid, detection of ... available in vitro system that uniquely simulates ... primary hemostasis. The system measures platelet function ... environment of a partially occluded blood vessel. ...
... A complete range of automatic systems for ... 1 mL of blood. With the introduction ... the clinical diagnostic market a truly revolutionary ... technical limitation associated with the traditional ESR ...
... NEW VACUETTE® erythrocyte sedimentation rate ... help. The new generation unites the ... with whole range of additional innovations ... the erythrocyte sedimentation rate. Cost effectiveness ...
Blood sedimentation rate analysis...
Medicine Products: